Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival

Bhutta, Abdul; Garcia-Tsao, G.; Reddy, Raja; Tandon, Parul; Wong, Florence; O’Leary, Jacqueline G.; Acharya, Chathur; Banerjee, D.; Abraldes, J.G.; Plener, Ian; Jones, Tiana M.; Shaw, Joshua; Deng, Yangyang; Ciarleglio, Maria; Bajaj, J.S.

doi:10.1016/s0168-8278(16)00253-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Very recently, Bhutta et al 76 published data in abstract form from non-elective hospitalised patients with cirrhosis with ascites from the NACSELD database. The cohort consisted of 717 patients, 51% had RA, 19% SBP and 43% were on NSBBs at admission.…”

Section: Introductionmentioning

confidence: 99%

Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function

Blasco-Algora

Masegosa-Ataz

Alonso

et al. 2016

BMJ Open Gastroenterol

View full text Add to dashboard Cite

IntroductionNon-selective β-blockers (NSBBs) are widely prescribed in patients with cirrhosis for primary and secondary prophylaxis of bleeding oesophageal varices. Furthermore, it has been suggested that the clinical benefits of NSBBs may extend beyond their haemodynamic effects. Recently, a potentially harmful effect has been described in patients with refractory ascites or spontaneous bacterial peritonitis.MethodologyA comprehensive literature search on β-blockers and cirrhosis survival using the electronic databases PubMed/MEDLINE, AMED, CINAHL and the Cochrane Central Register of Controlled Trials. Full-text manuscripts published over more than 35 years, from 1980 to April 2016 were reviewed for relevance and reference lists were cross-checked for additional pertinent studies regarding potential NSBB effects, especially focused on those concerned with survival and/or acute kidney injury (AKI).DiscussionThe proposed review will be able to provide valuable evidence to help decision making in the use of NSBB for the treatment of advanced cirrhosis and highlights some limitations in existing evidence to direct future research.

show abstract

Section: Introductionmentioning

confidence: 99%